DTX 101

Drug Profile

DTX 101

Alternative Names: AAVrh10FIX; DTX101; Wild-type FIX AAVrh10 vector

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dimension Therapeutics
  • Class Antihaemorrhagics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haemophilia B

Most Recent Events

  • 07 Nov 2017 Dimension Therapeutics has been acquired by Ultragenyx Pharmaceutical
  • 10 May 2017 Dimension Therapeutics terminates a phase I/II trial in Haemophilia B in USA and Bulgaria as the analysis did not meet the company's minimum target product profile for continued development or future commercialisation (Parenteral) (NCT02618915)
  • 10 May 2017 Discontinued - Phase-I/II for Haemophilia B in USA and Bulgaria (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top